Last reviewed · How we verify
BIIB028
At a glance
| Generic name | BIIB028 |
|---|---|
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- TAS-116 Plus Palbociclib in Breast and Rb-null Cancer (PHASE1)
- A Study of TAS-116 in Patients With Solid Tumors (PHASE1)
- Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer (PHASE1)
- A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. (PHASE1)
- A Study of DS-2248 in Participants With Advanced Solid Tumors (PHASE1)
- The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis
- PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (PHASE1)
- Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIIB028 CI brief — competitive landscape report
- BIIB028 updates RSS · CI watch RSS
- Biogen portfolio CI